Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All sarilumab studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchSarilumabSarilumab (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Gordon et al., New England Journal of Medicine, doi:10.1056/NEJMoa2100433, REMAP-CAP, NCT02735707
Apr 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality, concurrent 26% Improvement Relative Risk Mortality, inc. non-concur.. 50% Sarilumab  REMAP-CAP  LATE TREATMENT  RCT Is late treatment with sarilumab beneficial for COVID-19? RCT 442 patients in multiple countries Lower mortality with sarilumab (not stat. sig., p=0.39) c19early.org Gordon et al., New England J. Medicine, Apr 2021 Favorssarilumab Favorscontrol 0 0.5 1 1.5 2+
RCT 803 critically ill COVID-19 patients showing improved outcomes with tocilizumab and sarilumab. There was only 48 sarilumab patients and the model used shrinks the posterior distribution for each intervention effect toward the overall estimate for the combined drugs. The concurrent event counts for sarilumab may be more accurate.
risk of death, 26.3% lower, RR 0.74, p = 0.39, treatment 10 of 45 (22.2%), control 19 of 63 (30.2%), NNT 13, concurrent control patients.
risk of death, 50.2% lower, HR 0.50, p = 0.048, treatment 45, control 397, inverted to make HR<1 favor treatment, including non-concurrent control patients.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gordon et al., 22 Apr 2021, Randomized Controlled Trial, multiple countries, peer-reviewed, 62 authors, trial NCT02735707 (history) (REMAP-CAP).
This PaperSarilumabAll
{ 'indexed': {'date-parts': [[2024, 9, 23]], 'date-time': '2024-09-23T04:22:51Z', 'timestamp': 1727065371588}, 'reference-count': 21, 'publisher': 'Massachusetts Medical Society', 'issue': '16', 'license': [ { 'start': { 'date-parts': [[2021, 4, 22]], 'date-time': '2021-04-22T00:00:00Z', 'timestamp': 1619049600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://www.nejmgroup.org/legal/terms-of-use.htm'}], 'funder': [ { 'DOI': '10.13039/100010270', 'name': 'Wellcome Trust Innovations Project', 'doi-asserted-by': 'publisher', 'award': ['215522'], 'id': [{'id': '10.13039/100010270', 'id-type': 'DOI', 'asserted-by': 'publisher'}]}, { 'DOI': '10.1039/501100000272', 'name': 'National Institute for Health Research, Research Professorship', 'doi-asserted-by': 'publisher', 'award': ['RP-2015-06-18'], 'id': [{'id': '10.1039/501100000272', 'id-type': 'DOI', 'asserted-by': 'publisher'}]}, { 'DOI': '10.1039/501100000272', 'name': 'National Institute for Health Research, Clinician ScientistNational Institute for ' 'Health Research, Research Professorship', 'doi-asserted-by': 'publisher', 'award': ['CS-2016-16-011'], 'id': [{'id': '10.1039/501100000272', 'id-type': 'DOI', 'asserted-by': 'publisher'}]}, { 'DOI': '10.13039/100011102', 'name': 'European Union, FP7', 'doi-asserted-by': 'publisher', 'award': ['#602525'], 'id': [{'id': '10.13039/100011102', 'id-type': 'DOI', 'asserted-by': 'publisher'}]}, { 'DOI': '10.13039/501100007601', 'name': 'European Union Horizon 2020', 'doi-asserted-by': 'publisher', 'award': ['#101003589'], 'id': [{'id': '10.13039/501100007601', 'id-type': 'DOI', 'asserted-by': 'publisher'}]}, { 'DOI': '10.13039/501100000925', 'name': 'Australian National Health and Medical Research Council', 'doi-asserted-by': 'publisher', 'award': ['#APP1101719'], 'id': [{'id': '10.13039/501100000925', 'id-type': 'DOI', 'asserted-by': 'publisher'}]}, { 'DOI': '10.13039/501100001505', 'name': 'Health Research Council of New Zealand', 'doi-asserted-by': 'publisher', 'award': ['#16/631'], 'id': [{'id': '10.13039/501100001505', 'id-type': 'DOI', 'asserted-by': 'publisher'}]}, { 'DOI': '10.13039/501100000024', 'name': 'Canadian Institute of Health Research Strategy for Patient-Oriented Research ' 'Innovative Clinical Trials Program', 'doi-asserted-by': 'publisher', 'award': ['#158584'], 'id': [{'id': '10.13039/501100000024', 'id-type': 'DOI', 'asserted-by': 'publisher'}]}, { 'DOI': '10.13039/501100000272', 'name': 'National Institute for Health Research', 'doi-asserted-by': 'publisher', 'id': [{'id': '10.13039/501100000272', 'id-type': 'DOI', 'asserted-by': 'publisher'}]}, { 'DOI': '10.13039/100010415', 'name': 'Health Research Board of Ireland', 'doi-asserted-by': 'publisher', 'award': ['CTN 2014-012'], 'id': [{'id': '10.13039/100010415', 'id-type': 'DOI', 'asserted-by': 'publisher'}]}, { 'DOI': '10.13039/501100005737', 'name': 'UPMC Learning While Doing Program', 'doi-asserted-by': 'publisher', 'id': [{'id': '10.13039/501100005737', 'id-type': 'DOI', 'asserted-by': 'publisher'}]}, { 'DOI': '10.13039/100001006', 'name': 'Breast Cancer Research Foundation', 'doi-asserted-by': 'publisher', 'id': [{'id': '10.13039/100001006', 'id-type': 'DOI', 'asserted-by': 'publisher'}]}, { 'DOI': '10.13039/501100004571', 'name': 'French Ministry of Health', 'doi-asserted-by': 'publisher', 'award': ['PHRC-20-0147'], 'id': [{'id': '10.13039/501100004571', 'id-type': 'DOI', 'asserted-by': 'publisher'}]}, { 'DOI': '10.13039/501100016056', 'name': 'Minderoo Foundation', 'doi-asserted-by': 'publisher', 'id': [{'id': '10.13039/501100016056', 'id-type': 'DOI', 'asserted-by': 'publisher'}]}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2021, 4, 22]]}, 'DOI': '10.1056/nejmoa2100433', 'type': 'journal-article', 'created': {'date-parts': [[2021, 2, 25]], 'date-time': '2021-02-25T22:01:17Z', 'timestamp': 1614290477000}, 'page': '1491-1502', 'source': 'Crossref', 'is-referenced-by-count': 1326, 'title': 'Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19', 'prefix': '10.1056', 'volume': '384', 'author': [{'name': 'The REMAP-CAP Investigators', 'sequence': 'first', 'affiliation': []}], 'member': '150', 'reference': [ {'key': 'r2', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.17023'}, {'key': 'r3', 'doi-asserted-by': 'publisher', 'DOI': '10.1073/pnas.2005615117'}, {'key': 'r4', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.eclinm.2020.100553'}, {'key': 'r5', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciaa954'}, {'key': 'r6', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2028836'}, {'key': 'r7', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jamainternmed.2020.6820'}, {'key': 'r8', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jamainternmed.2020.6615'}, {'key': 'r9', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2030340'}, { 'key': 'r10', 'doi-asserted-by': 'crossref', 'first-page': '1503', 'DOI': '10.1056/NEJMoa2028700', 'volume': '384', 'author': 'Rosas IO', 'year': '2021', 'journal-title': 'N Engl J Med'}, {'key': 'r11', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.n84'}, {'key': 'r12', 'doi-asserted-by': 'publisher', 'DOI': '10.1513/AnnalsATS.202003-192SD'}, {'key': 'r13', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.17022'}, {'key': 'r14', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2019.14607'}, {'key': 'r15', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/pst.1589'}, {'key': 'r17', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2021436'}, {'key': 'r18', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S1473-3099(20)30483-7'}, {'key': 'r19', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)30566-3'}, {'key': 'r21', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.26085'}, {'key': 'r22', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-020-03065-y'}, {'key': 'r25', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMra2026131'}, {'key': 'r26', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2213-2600(20)30366-0'}], 'container-title': 'New England Journal of Medicine', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'http://www.nejm.org/doi/pdf/10.1056/NEJMoa2100433', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 4, 21]], 'date-time': '2021-04-21T21:07:44Z', 'timestamp': 1619039264000}, 'score': 1, 'resource': {'primary': {'URL': 'http://www.nejm.org/doi/10.1056/NEJMoa2100433'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 4, 22]]}, 'references-count': 21, 'journal-issue': {'issue': '16', 'published-print': {'date-parts': [[2021, 4, 22]]}}, 'alternative-id': ['10.1056/NEJMoa2100433'], 'URL': 'http://dx.doi.org/10.1056/NEJMoa2100433', 'relation': {}, 'ISSN': ['0028-4793', '1533-4406'], 'subject': [], 'container-title-short': 'N Engl J Med', 'published': {'date-parts': [[2021, 4, 22]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit